| 000 -LEADER |
|---|
| fixed length control field |
03860nam a22004215i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OSt |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20140310150647.0 |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
|---|
| fixed length control field |
cr nn 008mamaa |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
110601s2011 xxu| s |||| 0|eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9781607614784 |
|
978-1-60761-478-4 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC254-282 |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
616.994 |
| Edition number |
23 |
| 264 #1 - |
|---|
| -- |
Totowa, NJ : |
| -- |
Humana Press, |
| -- |
2011. |
| 912 ## - |
|---|
| -- |
ZDB-2-SME |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Gioeli, Daniel. |
| Relator term |
editor. |
| 245 10 - IMMEDIATE SOURCE OF ACQUISITION NOTE |
|---|
| Title |
Targeted Therapies |
| Medium |
[electronic resource] : |
| Remainder of title |
Mechanisms of Resistance / |
| Statement of responsibility, etc |
edited by Daniel Gioeli. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
XIV, 202 p. |
| Other physical details |
online resource. |
| 440 1# - SERIES STATEMENT/ADDED ENTRY--TITLE |
|---|
| Title |
Molecular and Translational Medicine |
| 505 0# - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Resistance to Targeted Therapies As a Result of Mutation(s) in the Target.- The Dynamics of the Cell Signaling Network; Implications for Targeted Therapies.- Cancer Signaling Network Analysis by Quantitative Mass Spectrometry.- Development and Implementation of Array Technologies for Proteomics: Clinical Implications and Applications.- Using Phosphoflow to Study Signaling Events of Sub Populations Resistant to Current Therapies -- Mathematical and Computational Models in Cancer -- Somatic Evolution of Acquired Drug Resistance in Cancer -- Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer -- MicroRNA: A Potential Therapy Able to Target Multiple Cancer Pathways -- Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance Mathematical and Computational Models in Cancer -- Somatic Evolution of Acquired Drug Resistance in Cancer -- Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer -- MicroRNA: A Potential Therapy Able to Target Multiple Cancer Pathways -- Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance Mathematical and Computational Models in Cancer -- Somatic Evolution of Acquired Drug Resistance in Cancer -- Interrogating Resistance to Targeted Therapy Using Genetically Engineered Mouse Models of Cancer -- MicroRNA: A Potential Therapy Able to Target Multiple Cancer Pathways -- Rational Combination of Targeted Agents to Overcome Cancer Cell Resistance. |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included. Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview as well as a detailed perspective on the mechanisms of resistance to targeted therapeutics and will be of great value to the oncologist, the physician-scientist treating patients and the translational scientist working on any aspect of targeted therapeutics. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Oncology. |
|
|---|
| Topical term or geographic name as entry element |
Medicine & Public Health. |
|
|---|
| Topical term or geographic name as entry element |
Oncology. |
|
|---|
| Topical term or geographic name as entry element |
Molecular Medicine. |
|
|---|
| Topical term or geographic name as entry element |
Cancer Research. |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
| 773 0# - HOST ITEM ENTRY |
|---|
| Title |
Springer eBooks |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
|---|
| Display text |
Printed edition: |
| International Standard Book Number |
9781607614777 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-60761-478-4 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
|
| Item type |
E-Book |
